Vedolizumab IV
( DrugBank: Vedolizumab / KEGG DRUG: Vedolizumab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 12 |
| 96 | Crohn disease | 67 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 83 |
94. Primary sclerosing cholangitis
Clinical trials : 177 / Drugs : 120 - (DrugBank : 48) / Drug target genes : 25 - Drug target pathways : 148
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,737 / Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. Ulcerative colitis
Clinical trials : 3,305 / Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|